Tagged with R&D

Belgium pharma.be is the association of the Belgian R&D-based pharmaceutical industry, representing over 42,000 employees at 130 companies. CEO Caroline Ven outlines the crucial role that pharma.be and its members played in Belgium’s COVID-19 response and recognition of the role that innovative pharma plays in Belgium. Ven also outlines the persistent…

Belgium Novartis is one of Belgian pharma’s biggest investors across manufacturing and R&D, contributing EUR 598.9 million to GDP in 2022, creating 4,403 direct and indirect jobs, and reaching 5,349,628 million patients via its locally available portfolio. 18 months into his role as Country President for BeLux, Federico Mambretti expands on…

Belgium While only Europe’s 34th biggest country by landmass and 13th by population, Belgium punches well above its weight in terms of key life sciences industry indicators, notably placing in the Top Five European countries for pharma R&D spending, pharma exports, and pharma imports. Made with Visme Infographic Maker   Made…

Italy ENEA Tech and Biomedical is a foundation supervised by the Italian Ministry of Economic Development that aims to strengthen Italian R&D and the industrial transformation of the country’s biomedical sector. Its managing director, Marco Baccanti, outlines the organisation’s strategy to support and fund projects and analyses the current state of…

Korea Stephen Yoo highlights the pioneering work that STCube Pharmaceuticals – a US subsidiary of Korean firm STCube – is undertaking in the immuno-oncology field, its three technology platforms, partnership approach, and his outlook for the company’s future.   Immuno-oncology has revolutionized cancer therapy, but despite the huge success there has…

China Writing in the April edition of DIA’s Global Forum magazine, the DIA China Leadership and Career Community look at the Chinese pharmaceutical innovation ecosystem’s R&D talent gap and the China Pharmaceutical R&D Talent Innovation Research Project that was launched to address it.   Over the past five years, China’s pharmaceutical innovation industry…

Korea KHIDI’s Soonman KWON outlines the public health R&D funding landscape in Korea, plans to increase Korea’s capacity to develop and produce its own vaccines in the wake of the COVID-19 pandemic, and how Korean infrastructure and expertise is helping train up scientists from low- and middle-income countries.   My hope…

Spain Lilly’s Nabil Daoud highlights the evolution in the firm’s Spanish manufacturing and R&D footprint in recent years, discussed launch plans for its next-generation diabetes and obesity treatments, and outlines some of the key trends currently impacting healthcare in Spain.   Four years ago, a molecule discovered and designed by scientists…

Global Speaking from Ipsen’s US headquarters in Cambridge, Massachusetts off the back of a whirlwind first 16 months as the firm’s Chief Business Officer, Philippe-Lopes Fernandes outlines his deal-making philosophy, how the iconic French mid-cap represents a reliable partner for innovative biotechs looking to establish a global reach for their programs,…

Spain mAbxience’s CEO Emmanuelle Lepine highlights the company’s international expansion into highly regulated markets, new investment into its Spanish manufacturing facility, and its partnership with AstraZeneca on COVID-19 vaccine manufacturing in Argentina. As representatives from the US FDA carried out a Good Clinical Practice inspection in an adjacent office, Lepine outlined…

Australia Australia’s international outlook, strong science base, multi-ethnic English-speaking population and high educational and regulatory standards make it an attractive location to undertake clinical trials for medicines and vaccines. These fundamentals were foregrounded during the COVID-19 pandemic, when Australia was able to pivot quickly and develop capabilities in technology and tele-monitoring…

Denmark Servier’s Estève Speranza outlines the rationale behind the French group’s reorganisation in the Nordic countries, how the global shift towards oncology is playing out in his region, and the Nordics’ relevance to Servier as an innovation hub and home to its antibody centre of excellence.   Servier is actively looking…